Johnson & Johnson's ICOTYDE Shows Sustained Efficacy in Difficult…

Event summary

Johnson & Johnson's ICOTYDE (icotrokinra) demonstrated sustained skin clearance in high-impact plaque psoriasis sites over two years.
89% of patients with genital psoriasis achieved complete skin clearance at Week 112.
The Phase 3 ICONIC-TOTAL study results were presented at the EADV Congress 2026.
ICOTYDE is the first and only targeted oral peptide blocking the IL-23 receptor.

The big picture

Johnson & Johnson's ICOTYDE represents a strategic advancement in treating high-impact plaque psoriasis, addressing a significant unmet need for patients with difficult-to-treat cases. The sustained efficacy data positions ICOTYDE as a potential first-line therapy, which could expand its market reach beyond current treatments. The collaboration with Protagonist Therapeutics underscores the importance of targeted oral therapies in the evolving landscape of psoriasis treatment.

What we're watching

Market Positioning: Whether ICOTYDE can establish itself as a first-line systemic therapy for difficult-to-treat psoriasis cases.
Regulatory Approvals: The pace at which ICOTYDE gains approvals for additional indications beyond plaque psoriasis.
Competitive Dynamics: How ICOTYDE's oral peptide mechanism differentiates it from existing IL-23 inhibitors in the market.